

Kenneth Vielsted Christensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8023673/publications.pdf>

Version: 2024-02-01

32
papers

972
citations

566801

15
h-index

476904

29
g-index

35
all docs

35
docs citations

35
times ranked

1850
citing authors

#	ARTICLE	IF	CITATIONS
1	The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. <i>Journal of Neuroimmunology</i> , 2006, 180, 71-87.	1.1	187
2	A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations. <i>Biological Psychiatry</i> , 2014, 76, 128-137.	0.7	95
3	Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. <i>Scientific Reports</i> , 2017, 7, 10300.	1.6	88
4	Recruitment of β -arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling. <i>Neuropharmacology</i> , 2008, 54, 1215-1222.	2.0	70
5	Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 48-58.	1.4	63
6	Asc-1 Transporter Regulation of Synaptic Activity via the Tonic Release of d-Serine in the Forebrain. <i>Cerebral Cortex</i> , 2017, 27, bhv350.	1.6	54
7	PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. <i>Toxicology</i> , 2018, 395, 15-22.	2.0	47
8	Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. <i>BMC Neuroscience</i> , 2010, 11, 9.	0.8	45
9	Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8945-8962.	2.9	41
10	Abnormal visual gain control in a Parkinson's disease model. <i>Human Molecular Genetics</i> , 2014, 23, 4465-4478.	1.4	39
11	A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission. <i>Translational Psychiatry</i> , 2017, 7, 1261.	2.4	37
12	Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. <i>British Journal of Pharmacology</i> , 2012, 167, 654-665.	2.7	30
13	Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV- β -synuclein is normalized by LRRK2 modulation. <i>Neurobiology of Disease</i> , 2018, 116, 13-27.	2.1	21
14	Design and Synthesis of Pyrrolo[2,3- <i>d</i>]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10312-10332.	2.9	21
15	Transcriptome analysis identifies activated signaling pathways and regulated ABC transporters and solute carriers after hyperosmotic stress in renal MDCK I cells. <i>Genomics</i> , 2019, 111, 1557-1565.	1.3	20
16	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. <i>Progress in Medicinal Chemistry</i> , 2017, 56, 37-80.	4.1	17
17	The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4500-4505.	1.0	15
18	Correlation of the expression of kainate receptor subtypes to responses evoked in cultured cortical and spinal cord neurones. <i>Brain Research</i> , 2002, 926, 94-107.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Glucocorticoid Receptor and Myocyte Enhancer Factor 2 Cooperate to Regulate the Expression of c-JUN in a Neuronal Context. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 209-218.	1.1	13
20	Larger intercellular variation in (Q/R) editing of GluR6 than GluR5 revealed by single cell RT-PCR. <i>NeuroReport</i> , 2000, 11, 3577-3582.	0.6	7
21	Measurement of cellular β -site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems. <i>Analytical Biochemistry</i> , 2009, 387, 208-220.	1.1	7
22	Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?. <i>Psychopharmacology</i> , 2011, 217, 525-538.	1.5	7
23	Support for a bipolar affective disorder susceptibility locus on chromosome 12q24.3. <i>Psychiatric Genetics</i> , 2010, 20, 93-101.	0.6	6
24	Classification of β -synuclein-induced changes in the AAV β -synuclein rat model of Parkinson's disease using electrophysiological measurements of visual processing. <i>Scientific Reports</i> , 2020, 10, 11869.	1.6	4
25	Long-Term Exposure to PFE-360 in the AAV β -Synuclein Rat Model: Findings and Implications. <i>ENeuro</i> , 2019, 6, ENEURO.0453-18.2019.	0.9	4
26	Nfat5 is involved in the hyperosmotic regulation of Tmem184b: a putative modulator of ibuprofen transport in renal MDCK I cells. <i>FEBS Open Bio</i> , 2019, 9, 1071-1081.	1.0	3
27	Ibuprofen transport in renal cell cultures: characterization of an ibuprofen transporter upregulated by hyperosmolarity. <i>MedChemComm</i> , 2016, 7, 1916-1924.	3.5	2
28	Over-expression, purification and characterization of an Asc-1 homologue from <i>Gloeobacter violaceus</i> . <i>Protein Expression and Purification</i> , 2010, 71, 179-183.	0.6	1
29	Progressive Effects of Sildenafil on Visual Processing in Rats. <i>Neuroscience</i> , 2020, 441, 131-141.	1.1	1
30	Recent Progress in Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors for the Treatment of Parkinson's Disease. <i>Medicinal Chemistry Reviews</i> , 2018, , 67-82.	0.1	1
31	B17 Characterisation Of A Huntington's Disease Cellular Model For The Transcriptome-based Expression Analysis Of Deubiquitinating Enzymes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A14-A15.	0.9	0
32	No detectable effect on visual responses using functional MRI in a rodent model of β -synuclein expression. <i>ENeuro</i> , 2021, 8, ENEURO.0516-20.2021.	0.9	0